Roche and Prothena will advance prasinezumab into late-stage clinical development study in Parkinson’s disease
The decision to move this monoclonal antibody that targets alpha-synuclein, a protein found in neurons, into a Phase 2b study in patients with early Parkinson’s disease, was based on positive signals of efficacy consistent with disease modification in the PASADENA study.
Source:
Biospace Inc.